The Impurities Forum Part II - Live Online Training Nitrosamines and other Mutagenic Impurities

Friday, 10 November 2023 8 .30 - 15.45 h

Seminar Nr. 20647

This course is part of the GMP Certification Programme "ECA Certified Quality Control Manager". Learn more.

All times mentioned are CET

Unser Seminarservice

Kosten

*ECA-Member:**	EUR 990,--
*Regular Fee:**	EUR 1190,--
*EU/GMP Inspectorates:**	EUR 595,--
*APIC Member Discount:**	EUR 1090,--

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

Zur Anmeldung

* auch unkompliziert per Kreditkarte bezahlbar

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de

Sprecher

Dr Cornelia Nopitsch-Mai, Quality Assessor, Germany
Dr Ulrich Rose, Former Deputy Head of the European Pharmacopoeia Department, EDQM, France
Dr Reinhard Stidl, Safetree Consulting, Austria
Dr Andrew Teasdale, Astra Zeneca, UK

Zielsetzung

In Part II of the Impurities Forum the relevant aspects of root cause analysis and risk assessment with respect to potential Nitrosamine contamination in drug substances and drug products will be discussed. You will hear what you need to know about the required risk assessments for medicinal products containing chemically synthesized APIs. In particular you will learn

which root causes for Nitrosamine Impurities should be considered,
which practical approaches can be applied to assess the risks related to potential Nitrosamine contamination,
which safety aspects need to be considered regarding Nitrosamine Impurities in drug products,
which regulatory actions are to be taken in case of Nitrosamine Impurities and what authorities expect in these cases.

You will get advice from industry experts on how to cope with the challenge of performing risk assessments. Furthermore, you will be informed about the European Pharmacopoeia activities on Nitrosamines and other mutagenic impurities.

Hintergrund

Mutagenic substances as impurities in drug substances or drug products are of big concern as they have the potential to alter or damage human DNA. Among these species Nitrosamines and elemental impurities have triggered various regulatory activities and initiatives. Since September 2019, Marketing Authorisation Holders are requested to evaluate the risk of the presence of Nitrosamine impurities in human medicinal products containing chemically synthesised APIs. In case of a contamination with Nitrosamines, MAHs are requested to file a variation application. The deadline for submission of variations has been extended once again and needs to be filed within 2023.The ICH Q3D Guideline for Elemental Impurities was published as Step 4 document and has meanwhile been revised twice, regarding Cadmium Inhalation PDE and cutaneous and transdermal products.

Zielgruppe

The Live Online Training addresses all personnel involved in development of drug substances and drug products from scientific staff to laboratory heads involved in R&D. The needs of Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments will also be covered. This Live Online Training will also address regulatory requirements and hence is applicable to people working in the Regulatory Affairs area.

Technical Requirements

We use WebEx for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programm

Part 2

European Pharmacopoeia Activities on Nitrosamines and other Mutagenic Impurities

Ph. Eur. General policy on DNA reactive impurities
Control of Nitrosamines in Ph. Eur.
Changes in individual and general monographs following the Sartan case
New general chapter on control of nitrosamines

Root Causes for Nitrosamine Impurities and other Mutagenic Impurities – Practical Approaches to Assess the Risks

Development of a systematic risk-based approach
Key factors and the development of a decision tree
- API
- Drug product
- Packaging

Safety Qualification of Impurities - Current Principles and Methods

General approaches and regulatory framework for impurity qualification by safety threshold Derivation
Generic and substance specific safety thresholds
Threshold of Toxicological Concern (TTC) - different Scenarios
Derivation of Permitted Daily Exposure (PDE) Limits
Acceptable exposure calculations based on TD50 and their limitations
Approaches for data poor substances: (Q)SARs and read-across
Route-to-route considerations for safety thresholds

Nitrosamines and Other Genotoxic Impurities – Authorities Expectations and Dossier Requirements

The assessor’s approach: principles of toxicological assessment
Structural alerts
Limits and Permitted Daily Exposure
The ALARP principle
Examples of low daily dose drug substances
Impurities derived from alkylating agents (mesilate, besilate, tosilate, diisothionate); examples
Nitrosamines – the Valsartan case
Potential mutagenic residual solvents
Impurities derived from metal catalysts

Workshop: Conducting a Nitrosamine Risk Assessment

In this Workshop the participants will work on several case studies and perform a risk assessment for different scenarios taking into account e.g. manufacturing equipment, dosage form of the drug product etc.

Zurück